Boehringer Ingelheim, Eli Lilly sales and marketing update

The U.K.’s NICE issued final guidance recommending Jardiance empagliflozin from Boehringer Ingelheim to treat Type II diabetes. Specifically, Jardiance is recommended in a dual therapy regimen in combination with metformin only if a sulfonylurea is contraindicated or not tolerated or if the patient is at significant risk of hypoglycemia or its consequences; in a triple therapy regimen with metformin and either sulfonylurea or a thiazolidinedione; and in combination with insulin with or without other antidiabetic drugs. The final guidance is in line with draft guidance issued in January (see BioCentury, Jan. 26). ...